Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Gains from Investment Securities: 2022

  • Northwest Biotherapeutics' Gains from Investment Securities was N/A to $304.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $304.6 million, marking a year-over-year change of. This contributed to the annual value of $364,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2022, Northwest Biotherapeutics' Gains from Investment Securities is $304.6 million.
  • In the past 5 years, Northwest Biotherapeutics' Gains from Investment Securities ranged from a high of $304.6 million in Q3 2022 and a low of $304.6 million during Q3 2022.
  • Moreover, its 1-year median value for Gains from Investment Securities was $304.6 million (2022), whereas its average is $304.6 million.